Table 1. EGFR-directed monoclonal antibodies in advanced NSCLC.

Monoclonal antibody	Clinical development
	Phase	Status
Cetuximab	Phase III	completed
Matuzumab	Phase II	completed
Panitumumab	Phase II	completed
Necitumumab	Phase III	ongoing